RecruitingPhase 1Phase 2NCT05026632

NPI-002 Intravitreal Implant for the Delay of Cataract Progression

Safety and Efficacy of NPI-002 Intravitreal Implant for the Delay of Cataract Progression in Patients Undergoing Vitrectomy


Sponsor

Nacuity Pharmaceuticals, Inc.

Enrollment

30 participants

Start Date

Jan 27, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

This study will examine the safety and efficacy NPI-002 intravitreal implants post vitrectomy.


Eligibility

Min Age: 18 Years

Inclusion Criteria3

  • Indicated for vitrectomy
  • Natural Lens in place at time of vitrectomy
  • Some cataract present as assessed pre-operatively

Exclusion Criteria11

  • Previous intraocular surgery in study eye.
  • Clear zonular weakness or defects / coloboma.
  • Not on stable dose of medications for other conditions.
  • Need for oral corticosteroids during study participation.
  • Evidence or history of uveitis, or ocular ischemia.
  • Current smoker
  • Use of supplemental oxygen
  • Evidence or history of proliferative diabetic retinopathy.
  • Current lung disease (PU, COPD, Asthma) resulting in decreased oxygen saturation.
  • Sensitivity to thiol compounds.
  • Participation in another clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGNPI-002 Intravitreal Implant

Implant inserted during vitrectomy.


Locations(1)

Royal Adelaide Hospital

Adelaide, Australia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05026632


Related Trials